You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Enigma struck the alliance with Tecan in anticipation of a fourth-quarter commercial launch of its miniaturized PCR instrument for point-of-care influenza diagnostic tests in Europe in partnership with GlaxoSmithKline.
Tecan will manufacture Enigma's new point-of-care molecular diagnostic instrument under a five-year deal.
Chris Wagner, Brad Popovich, Jorge Garces, Greg Hamilton, Nick Williams, Darren Hall
The British molecular diagnostics firm also announced executive appointments for both the US and European operations.
The firms will develop tests to run on Enigma's ML platform. As part of the alliance, GSK will make an equity investment in the molecular diagnostics startup.
Enigma Diagnostics gained access to two Roche patents for use in its multiplex PCR tests for human and animal diseases.
In Brief This Week is a Friday column containing news items that our readers may have missed during the week.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.